Clarus’ proprietary adjuvant is fully developed and successfully tested in multiple pre-clinical studies. Based on these results, and its applicability across multiple segments of the life sciences industry, we believe CBI-3A provides a unique solution to existing vaccine market challenges. In addition, our business development strategy is designed to exploit key differences in entry to applicable market segments, reducing risk and accelerating to positive cash flow.

Please contact us if you would like to know more about this unique and compelling investment opportunity.